Primary health care will include the use of Biomodulin T, based on the positive results of this Cuban medicine in the treatment of infections in children and older adults.
Miguel Díaz-Canel, First Secretary of the Central Committee of the Communist Party of Cuba and President of the Republic, indicated in a meeting with health experts to expedite the process so that the drug can be prescribed in Cuban communities, the Presidency reported on the website of he.
The decision, the report indicates, is based on the results of clinical trials carried out in the country with Biomodulin T, whose base is bovine thymus extract, and is indicated for immune dysfunction and the treatment of recurrent infections in adults. greater.
Doctor of Science Alexis Labrada Rosado, director of research and development of the National Center for Biopreparations (Biocen), stated that as a conclusion of a study with almost nine thousand patients admitted to nursing homes, a reduction in the frequency of infections was proven. acute respiratory infections (ARI) by just over five times.
During the meeting, which took place at the Palace of the Revolution, the specialist stated that the risk of dying from this cause was reduced by half in the elderly who reside in these health institutions, when compared with those who, at the same ages, , they are out of nursing homes.
He explained that clinical trials also demonstrated that after the administration of Biomodulin T in older adults, a 70 percent (%) decrease in the incidence of respiratory infections was achieved, which are today the leading cause of death in the elderly. nursing homes in the country.
Biomodulin T has also shown safety and efficacy in the treatment of thymic hypoplasia in children, a genetic disease that causes infants in the first years of life to suffer a high percentage of infections.
According to Labrada Rosado, 83% of the children treated with the medication normalized the size of their thymus and its function, and 71% had clinical improvement criteria.
Likewise, this drug has also been studied with very good results in oncology, from combined treatment with cancer chemotherapy and immunotherapy, the researcher said, and commented that the patients' immune system is rejuvenated, and they have more capacity. to counteract the disease.
Biomodulin T reached its greatest momentum during the COVID-19 pandemic, when Biocen marketed 1,988,953 units, and more than 238,000 patients were treated.
This medicine of excellence, with health registration in the country since 1994, won two awards from the Academy of Sciences in 2022, precisely for its results as part of the treatment of patients with lung cancer, and its immunomodulatory effects in older adults residing in nursing homes, highlights the Presidency's text.
taken from cubadebate.cu